Influential Analyst Rating Changes: Sangamo Therapeutics, Inc. (SGMO), Portola Pharmaceuticals, Inc. (PTLA)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) tinted gains of +3.55% (+0.39 points) to US$11.38. The volume of 2.14 Million shares climbed up over an trading activity of 1.95 Million shares. EPS ratio determined by looking at last 12 month figures is -0.69. Over the same time span, the stock marked US$27.5 as its best level and the lowest price reached was US$9. The corporation has a market cap of US$1.16 Billion.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO)’s earnings per share has been growing at a -10.6 percent rate over the past 5 year when average revenue increase was noted as 11 percent. The return on equity ratio or ROE stands at -22.1 percent while most common profitability ratio return on investment (ROI) was -26.5 percent. The company’s institutional ownership is monitored at 66.4 percent. The company’s net profit margin has achieved the current level of -88.8 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 3 think it is Hold. Recently, analysts have updated the overall rating to 2. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) is worth US$1.59 Billion and has recently risen 3.54% to US$23.99. The latest exchange of 1.74 Million shares is below its average trading activity of 1.83 Million shares. The day began at US$23.08 but the price moved to US$23.03 at one point during the trading and finally capitulating to a session high of US$24.23. The stock tapped a 52-week high of US$55.48 while the mean 12-month price target for the shares is US$35.83.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 9.63, and a price to sales ratio of 45.88. For the past 5 years, the company’s revenue has grown -20.7%, while the company’s earnings per share has grown 0%. With an institutional ownership near 0%, it carries an earnings per share ratio of -5.38.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.86.